艾滋病 z-bo 2020-09-24 747

　　The HIV prevention vaccine has been clinically tested in South Africa. If successful, it may cause a "dead blow" to AIDS and safely prevent HIV infection. This AIDS vaccine called HVTN702 is an improvement of the RV144 AIDS vaccine, which was clinically tested in Thailand in 2009. In three and a half years of clinical trials, the effectiveness of RV144 was 31%, which is the date when it first helped some people. We provide protective AIDS vaccines. Researchers hope that HVTN702 can provide more effective and lasting protection than RV144.

　　The clinical trial recruited 5,400 healthy adults aged 18-35 who have a high risk of infection. This is the largest AIDS vaccine clinical trial in South Africa's history. HVTN702 is suitable for HIV subtypes prevalent in southern Africa. Participants received five vaccinations each year and were randomly assigned a vaccine or placebo. Researchers carefully monitored the effectiveness and potential side effects of the new vaccine. The results of the survey will be announced at the end of 2020. in

　　A small study of more than 200 people showed that HVTN702 is safe to use.

　　The latest AIDS vaccine clinical trial is jointly funded by the National Institute of Allergy and Infectious Diseases (NIAID), the US Army, the South African Medical Research Council, and the Bill and Melinda Gates Foundation. Today, 37 million people worldwide are directly infected with AIDS, and about 1 million people die every year. In South Africa, more than 1,000 people are infected with HIV every day.

　　IAID Director Anthony Fauci said: “There is no existing AIDS prevention strategy overview that can completely stop the spread of the virus. In the future, safe and effective vaccines will complete the “last blow” to HIV. Even moderately effective vaccines will be Can significantly reduce the number of HIV infections, thereby reducing the burden of treatment in high-incidence countries such as South Africa.